NNRTIs in Development: Overview
- An Overview of Lersivirine (May 29, 2013)
From AIDSinfo
 ARV Pipeline: Dolutegravir, TAF (GS-7340), MK-1439 and Cenicriviroc (March/April 2013)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
- MK-1439 -- A Novel NNRTI For HIV Treatment (Video) (March 15, 2013)
From HIVandHepatitis.com
- Merck's Non-Nuke MK-1439 Shows Antiviral Activity, Is Safe and Well Tolerated (March 11, 2013)
From AIDSmeds.com
- Novel Drug Shows "Strong" Anti-HIV Effect (March 6, 2013)
From MedPage Today
- New NNRTI MK-1439 Shows Promise in Early Clinical Trial (March 6, 2013)
From aidsmap.com
- Seven-Day Monotherapy With New NNRTI Yields Sharp Viral Load Drop (March 5, 2013)
From National AIDS Treatment Advocacy Project
- Merck Acquires CMX157 and EFdA and Starts Phase 2 Study for New NNRTI (September/October 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
- Studies on Pipeline Antiretrovirals Reveal New Data on Possible Drug Interactions (May/June 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
- New Drug Adds to Arsenal Against AIDS (July 25, 2011)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- MSF Letter Criticizes Johnson & Johnson for Not Joining Medicines Patent Pool (April 26, 2011)
In Kaiser Daily Global Health Policy Report, from Henry J. Kaiser Family Foundation
- ViiV/GSK NNRTI "761" Development Placed on Hold by FDA (February 16, 2011)
From Test Positive Aware Network
- GSK New NNRTI Selects No Resistance Mutations in 7 Days of Monotherapy (September 15, 2010)
From National AIDS Treatment Advocacy Project
- Peering in the Pipeline (Summer 2009)
To read PDF, click here.
In Achieve, from ACRIA and GMHC
- Two NNRTIs in Early Development Show Promising Results (August 7, 2008)
From Project Inform
- New Drugs From Old Classes (Spring 2006)
A listing of NNRTIs, NRTIs and protease inhibitors currently in development.
To read PDF, click here.
In ACRIA Update, from AIDS Community Research Initiative of America
- NNRTIs in Development (March 30, 2006)
An overview from Edwin DeJesus, M.D.
From TheBody.com
- BILR 355 BS, a Second-Generation NNRTI, Shows Activity Against Most Common NNRTI Mutations (December 17, 2005)
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
- GW695634 Demonstrates Potent Activity in 7-Day Monotherapy Study in an NNRTI Treatment-Experienced Population (July 27, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
- Pfizer Discontinues Development of Capravirine, for HIV/AIDS (July 1, 2005)
From Pfizer, Inc.
- Early Pre-Clinical Development of GW8248 Promising (September 14, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from TheBodyPRO.com
|
Advertisement
|
Email
Glossary
